Letter by Filippidis et al Regarding Article, “Evaluating Strategies for the Treatment of Cerebral Cavernous Malformations”

To the Editor:In the October issue of Stroke , we read with great interest the recent article by Li and Whitehead1 documenting the role of RhoA hyperactivation in the pathophysiology of cerebral cavernous malformations (CCMs) and suggesting a potential role for statins to treat these lesions. The authors tried to unveil novel strategies in the field of a noninvasive drug treatment approach for CCMs; however, this article focuses only on statins. Other candidate drugs, like the β-adrenergic receptor blocker, propranolol, demonstrate promising results concerning CCMs and infantile capillary hemangiomas.2,3 In our current communication, we postulate that oral propranolol administration could provide a novel, alternative approach for the treatment of adults and children with familial cavernous malformation cases of the central nervous system.Recently, Moschovi et al3 …